Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Platinum Refractory Disease.
Study Type: Treatment
Phase: III
NCTID: NCT06589804
Principal Investigator:
Prakash Neupane
Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Study Type: Treatment
Phase: II/III
NCTID: NCT01810913
Principal Investigator:
Chris Lominska
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer
Study Type: Treatment
Phase: II/III
NCTID: NCT03952585
Principal Investigator:
Chris Lominska
A Multicenter, Randomized, Double-blind, Placebo-Controlled, Phase III Study of Ficlatuzumab in Combination with Cetuximab in Participants with Recurrent or Metastatic R/M HPV-Negative Head and Neck Squamous Cell Carcinoma FIERCE-HN
Phase III Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination with Cetuximab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor.
The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma HNSCC with HRAS Mutations AIM-HN and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC SEQ-HN.
Phase 1b Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Repeated Doses of DB-020 in Patients Receiving Cisplatin
A Phase III Randomized Placebo-Controlled Double-Blind Clinical Study of Pembrolizumab Mk-3475 With or Without Lenvatinib E7080/Mk-7902 to Evaluate the Safety and Efficacy of Pembrolizumab and Lenvatinib as 1L Intervention in a PD-L1 Selected Population of Participants with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma R/M HNSCC LEAP-010
TEMPUS PHOENIX HNSCC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Head Neck Squamous Cell Carcinoma HNSCC
Study Type: Other
Phase: N/A
NCTID: NCT06163534
Principal Investigator:
Prakash Neupane
A Double Blind, Placebo Controlled Dose Range Finding Study to Assess the Safety, Pharmacokinetics, and Efficacy of Tempol for the Reduction of Severe Mucositis in Head and Neck Cancer Patients Undergoing Combined Radio- and Chemotherapy
Study Type: Treatment
Phase: II
NCTID: NCT03480971
Principal Investigator:
Chris Lominska